Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH‐CTD): Real‐world experience from EXPOSURE

Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH‐CTD): Real‐world experience from EXPOSURE

Abstract Selexipag is indicated for the treatment of pulmonary arterial hypertension (PAH), including PAH associated with connective tissue disease (CTD), and further insights into the management of selexipag‐treated PAH‐CTD patients in clinical settings are needed. These analyses of the ongoing, mu...

Full description

Bibliographic Details
Main Authors: Sean Gaine, Pilar Escribano‐Subias, Audrey Muller, Catarina C. Fernandes, Martina Fontana, Tatiana Remenova, Stefan Söderberg, Tobias J. Lange
Format: Article
Language:English
Published: Wiley 2024-07-01
Series:Pulmonary Circulation
Subjects:
real‐world evidence
registry
scleroderma
survival
treatment patterns
Online Access:https://doi.org/10.1002/pul2.12403

Internet

https://doi.org/10.1002/pul2.12403

Similar Items